Antithrombotische Therapie bei pAVK und Aortenerkrankungen

Zusammenfassung

Patienten mit peripherer arterieller Verschlusskrankheit (pAVK) oder Aortenerkrankungen haben ein hohes Risiko für kardiovaskuläre Ereignisse. Gerinnungshemmende Medikamente verbessern die Prognose und haben daher einen hohen Stellenwert. Bei jeder gerinnungshemmenden Therapie sollte das individuelle Blutungsrisiko berücksichtigt werden und eine individuelle Nutzen-Risiko-Abwägung durchgeführt werden. Patienten mit symptomatischer pAVK sollten einen Thrombozytenaggregationshemmer (TZAH) erhalten. Bei hohem Risiko für kardiovaskuläre Ereignisse und niedrigem Blutungsrisiko wird die Kombination von Acetylsalicylsäure (ASS) 100 mg und Rivaroxaban 2 × 2,5 mg empfohlen. Liegt ein hohes Blutungsrisiko vor, ist Clopidogrel ASS vorzuziehen. Bei Patienten mit Aortenerkrankungen (z. B. komplexe Plaques, Aortenaneurysma) ist die Gabe eines TZAH indiziert. Patienten mit einer atherosklerotischen Gefäßerkrankung und Indikation für eine orale Antikoagulation wegen Vorhofflimmern oder venöser Thromboembolie sollten keinen zusätzlichen TZAH erhalten. Denn dieser erhöht das Blutungsrisiko, ohne die Prognose zu verbessern.

Abstract

Patients with lower extremity arterial disease (LEAD) or aortic diseases are at increased risk for cardiovascular events. Antithrombotic drugs are highly indicated because they improve the prognosis. Individual bleeding risk should be assessed in each case. Patients with symptomatic LEAD should receive an antiplatelet drug. In patients with high thrombotic and low bleeding risk the combination of acetyl salicylic acid (ASA) 100 mg and rivaroxaban 2.5 mg twice daily is indicated. In patients with high bleeding risk single antiplatelet therapy is recommended and Clopidogrel should be preferred over ASA. In patients with aortic disease (complex plaques, aortic aneurysm) antiplatelet drugs are indicated. If full dosage anticoagulation is indicated because of concomitant atrial fibrillation or venous thromboembolism there is no need for additional antiplatelet therapy because of no benefit and increase of bleeding risk.

Schlüsselwörter

Thrombozytenaggregationshemmer - Aortenerkrankungen - periphere arterielle Verschlusskrankheit

Keywords

lower extremity arterial disease - aortic diseases - antiplatelet therapy

• Literatur

• 1 Aboyans V, Ricco JB, Bartelink MEL. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018; 39: 763-816
• 2 Aboyans V, Bauersachs R, Mazzolai L. et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J 2021; 42: 4013-4024
• 3 Eikelboom JW, Connolly SJ, Bosch J. et al. Rivaroxaban with or without Aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330
• 4 Anand SS, Bosch J, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229
• 5 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994-2004
• 6 Hess CN, Rogers RK, Wang TY. et al. Major adverse limb events and 1-year outcomes after peripheral artery revascularization. J Am Coll Cardiol 2018; 72: 999-1011
• 7 Belch J, MacCuish A, Campbell I. et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
• 8 Fowkes FG, Price JF, Stewart MC. et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303: 841-848
• 9 Lawall H, Huppert P, Rümenapf G. et al. S3-Leitlinien zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. 2015 Zugriff am 21. September 2022 unter: https://www.awmf.org/leitlinien/detail/ll/065–003.html
• 10 Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
• 11 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
• 12 Bhatt DL, Fox KA, Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717
• 13 Cacoub PP, Bhatt DL, Steg PG. et al. Patients with peripheral arterial disease in the CHARISMA Trial. Eur Heart J 2009; 30: 192-201
• 14 Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-227
• 15 Hiatt WR, Fowkes FG, Heizer G. EUCLID Trial Steering Committee and Investigators. et al. Ticagrelor versus Clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376: 32-40
• 16 Tepe G, Bantleon R, Brechtel K. et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy – the MIRROR study: A randomized double-blinded clinical trial. Eur Radiol 2012; 22: 1998-2006
• 17 Iida O, Yokoi H, Soga Y. et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013; 127: 2307-2315
• 18 Moll F, Baumgartner I, Jaff M. et al. Edoxaban plus Aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD Trial. J Endovasc Ther 2018; 25: 158-168
• 19 Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticuagulants or Aspirin Study): a randomised trial. Lancet 2000; 355: 346-351
• 20 Sarac TP, Huber TS, Back MR. et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg 1998; 28: 446-457
• 21 Belch JJ, Dormandy J. CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825-833
• 22 Hiatt WR, Bonaca MP, Patel MR. et al. Rivaroxaban and Aspirin in peripheral artery disease lower extremity revascularization. Impact of concomitant Clopidogrel on efficacy and safety. Circulation 2020; 142: 2219-2230
• 23 Di Tullio MR, Russo C, Jin Z. Patent Foramen Ovale in Cryptogenic Stroke Study Investigators. et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009; 119: 2376-2382
• 24 Ruggiero A, Gonzáles-Alujas T, Rodríguez J. et al. Aortic intramural haematoma and chronic anticoagulation: role of transoesophageal echocardiography. Eur J Echocardiogr 2008; 9: 56-57
• 25 Marzelle J, Presles E, Becquemin JP. et al. Results and factors affecting early outcome of fenestrated and/or branched stent grafts for aortic aneurysms: a multicenter prospective study. Ann Surg 2015; 261: 197-206
• 26 Lamberts M, Lip GY, Ruwald MH. et al. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and vascular disease: a nationwide cohort study. J Am Coll Cardiol 2014; 63: 2689-2698